$CRH

CRH PUBLIC LTD CO

CIK:0000849395|SEC Filings

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Total revenues	$ 10,777	$ 10,206	$ 18,147	$ 16,962
Total cost of revenues	(6,483)	(6,180)	(11,808)	(11,099)
Gross profit	4,294	4,026	6,339	5,863
Selling, general and administrative expenses	(2,267)	(2,120)	(4,324)	(3,953)
Gain on disposal of long-lived assets	52	29	74	43
Loss on impairments	0	0	(48)	0
Operating income	2,079	1,935	2,041	1,953
Interest income	22	30	43	67
Interest expense	(220)	(200)	(423)	(381)
Other nonoperating income (expense), net	282	(9)	278	(29)
Income from operations before income tax expense and income from equity method investments	2,163	1,756	1,939	1,610
Income tax expense	(661)	(425)	(606)	(367)
Income (loss) from equity method investments	9	1	(2)	(9)
Net income	1,511	1,332	1,331	1,234
Net (income) attributable to redeemable noncontrolling interests	(10)	(8)	(10)	(8)
Net (income) attributable to noncontrolling interests	(15)	(5)	(11)	(1)
Net income attributable to CRH	$ 1,486	$ 1,319	$ 1,310	$ 1,225
Earnings per share attributable to CRH
Basic (in USD per share)	$ 2.22	$ 1.95	$ 1.94	$ 1.79
Diluted (in USD per share)	$ 2.21	$ 1.94	$ 1.93	$ 1.78
Weighted average common shares outstanding
Basic (in shares)	667.2	674.8	667.9	675.8
Diluted (in shares)	668.8	677.7	670.3	679.9
Product
Total revenues	$ 8,491	$ 7,919	$ 14,725	$ 13,531
Total cost of revenues	(4,429)	(4,083)	(8,680)	(7,909)
Service
Total revenues	2,286	2,287	3,422	3,431
Total cost of revenues	$ (2,054)	$ (2,097)	$ (3,128)	$ (3,190)

Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows from Operating Activities:
Net income	$ 1,331	$ 1,234
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, depletion, and amortization	1,124	1,005
Loss on impairments	48	0
Share-based compensation	73	66
Gain on disposals from businesses and long-lived assets, net	(334)	(12)
Deferred tax expense	31	5
Loss from equity method investments	2	9
Pension and other postretirement benefits net periodic benefit cost	0	12
Non-cash operating lease costs	164	134
Other items, net	6	2
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Accounts receivable, net	(1,824)	(1,397)
Inventories	(140)	(107)
Accounts payable	248	(58)
Operating lease liabilities	(167)	(153)
Other assets	(55)	(250)
Other liabilities	23	249
Pension and other postretirement benefits contributions	(21)	(20)
Dividends received from equity method investments	4	0
Net cash used in operating activities	513	719
Cash Flows from Investing Activities:
Purchases of property, plant and equipment, and intangibles	(1,240)	(1,300)
Acquisitions, net of cash acquired	(1,110)	(648)
Proceeds from divestitures	1,676	37
Proceeds from disposal of long-lived assets	96	65
Distributions received from equity method investments	0	13
Settlements of derivatives	(33)	(33)
Deferred divestiture consideration received	0	38
Other investing activities, net	23	33
Net cash used in investing activities	(588)	(1,795)
Cash Flows from Financing Activities:
Proceeds from debt issuances	1,552	4,542
Payments on debt	(1,129)	(3,352)
Settlements of derivatives	(40)	77
Payments of finance lease obligations	(73)	(46)
Deferred and contingent acquisition consideration paid	(18)	(13)
Dividends paid	(521)	(500)
Distributions to noncontrolling and redeemable noncontrolling interests	(23)	(22)
Transactions involving noncontrolling interests	(24)	2
Repurchases of common stock	(607)	(644)
Amounts related to employee share plans	(66)	(56)
Net cash used in financing activities	(949)	(12)
Effect of exchange rate changes on cash and cash equivalents, including restricted cash	(40)	205
Decrease in cash and cash equivalents, including restricted cash	(1,064)	(883)
Cash and cash equivalents and restricted cash at the beginning of period	4,147	3,759
Cash and cash equivalents and restricted cash at the end of period	3,083	2,876
Supplemental cash flow information:
Cash paid for interest (including finance leases)	335	251
Cash paid for income taxes	404	304
Reconciliation of cash and cash equivalents and restricted cash
Cash and cash equivalents presented in the Condensed Consolidated Balance Sheets	3,025	2,876
Restricted cash presented in the Condensed Consolidated Balance Sheets	58	0
Total cash and cash equivalents and restricted cash presented in the Condensed Consolidated Statements of Cash Flows	$ 3,083	$ 2,876

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025	Jun. 30, 2025
Current assets:
Cash and cash equivalents	$ 3,025	$ 4,096	$ 2,876
Restricted cash	58	51	0
Accounts receivable, net of allowance for credit losses of $136 million, $137 million, and $151 million as of June 30, 2026, December 31, 2025, and June 30, 2025, respectively	6,777	5,178	6,490
Inventories	5,103	5,251	5,051
Other current assets	789	678	734
Total current assets	15,752	15,254	15,151
Property, plant and equipment, net	24,885	24,937	23,017
Equity method investments	464	502	712
Goodwill	13,150	13,099	11,673
Intangible assets, net	2,037	2,048	1,239
Operating lease right-of-use assets, net	1,285	1,471	1,295
Other noncurrent assets	979	1,018	897
Total assets	58,552	58,329	53,984
Current liabilities:
Accounts payable	3,535	3,263	3,303
Accrued expenses	2,046	2,196	2,266
Current portion of long-term debt	2,516	1,175	1,171
Operating lease liabilities	258	286	247
Other current liabilities	1,622	1,834	1,697
Total current liabilities	9,977	8,754	8,684
Long-term debt	15,410	16,478	14,642
Deferred income tax liabilities	3,509	3,511	3,202
Noncurrent operating lease liabilities	1,069	1,232	1,096
Other noncurrent liabilities	3,052	2,876	2,730
Total liabilities	33,017	32,851	30,354
Commitments and Contingencies
Redeemable noncontrolling interests	435	430	389
Shareholders’ equity
Preferred stock, €1.27 par value, nil, 150,000 and 150,000 shares authorized and nil, 50,000 and 50,000 shares issued and outstanding for 5% preferred stock and nil, 872,000 and 872,000 shares authorized, issued and outstanding for 7% 'A' preferred stock, as of June 30, 2026, December 31, 2025, and June 30, 2025, respectively	0	1	1
Common stock, €0.32 par value, 1,250,000,000 shares authorized; 701,490,721, 706,946,142 and 711,792,599 issued and 665,895,636, 668,630,350 and 673,202,797 outstanding, as of June 30, 2026, December 31, 2025, and June 30, 2025, respectively	284	286	288
Treasury stock, at cost (35,595,085, 38,315,792 and 38,589,802 shares as of June 30, 2026, December 31, 2025, and June 30, 2025, respectively)	(1,896)	(2,016)	(2,028)
Additional paid-in capital	285	397	323
Accumulated other comprehensive loss	(376)	(257)	(345)
Retained earnings	25,738	25,593	24,106
Total shareholders’ equity attributable to CRH shareholders	24,035	24,004	22,345
Noncontrolling interests	1,065	1,044	896
Total equity	25,100	25,048	23,241
Total liabilities, redeemable noncontrolling interests and equity	$ 58,552	$ 58,329	$ 53,984